| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2543272 | Journal of the American Pharmacists Association | 2015 | 15 Pages |
Abstract
HCV, a well-known blood-borne disease associated with significant morbidity and mortality worldwide, can be effectively and safely treated with new anti-HCV agents such as SOF. While these new medications are in their early days of real-world practice, they offer hope that cure is truly possible.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Trang H. (PGY2 Hematology/Oncology Resident), Christopher J. (Professor of Pharmacy Practice), Renuga (Assistant Professor of Internal Medicine),